Hypersensitivity to the active substances, to ACE inhibitors, to dihydropyridines derivatives, or to any of the excipients listed in Description.
Severe renal impairment (see Dosage & Administration and Precautions).
History of angioedema associated with previous ACE inhibitor therapy.
Hereditary or idiopathic angioedema.
Second and third trimesters of pregnancy (see Precautions and Use in Pregnancy & Lactation).
Shock, including cardiogenic shock.
Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis).
Haemodynamically unstable heart failure after acute myocardial infarction.
Concomitant use of Viacoram with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see Interactions and Pharmacology: Pharmacodynamics under Actions).
Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see Interactions).
Significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney (see Precautions).
Concomitant use with sacubitril/valsartan therapy, Perindopril must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see Precautions and Interactions).